ARMATA PHARMACEUTICALS, INC. Shareholders' Equity
ARMATA PHARMACEUTICALS, INC. (ARMP) had Shareholders' Equity of -$231.17 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent -$231.17M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$311.59M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$218.60M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$95.59M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$231.17M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$311.59M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | -$218.60M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$95.59M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$69.50M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$53.78M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | -$48.02M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | -$50.97M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$46.10M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | -$56.51M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | -$32.06M 10-K · filed 2026-03-25 | |
| 2023-09-30 | -$12.39M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $19.14M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $22.45M 10-Q · filed 2024-08-13 | |
| 2022-12-31 | $36.08M 10-K · filed 2025-03-21 | |
| 2022-09-30 | $45.58M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $53.29M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $61.54M 10-Q · filed 2023-08-14 | |
| 2021-12-31 | $25.40M 10-K · filed 2024-03-21 | |
| 2021-09-30 | $23.75M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $28.62M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $34.01M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $18.86M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $24.62M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $29.64M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $33.48M 10-Q · filed 2021-08-12 | |
| 2019-12-31 | $14.59M 10-K · filed 2022-03-17 | |
| 2019-09-30 | $18.13M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $22.63M 10-Q · filed 2020-11-12 | $22.63M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $3.96M 10-Q · filed 2020-08-13 | $4.96M 10-Q · filed 2019-05-06 |
| 2018-12-31 | $7.69M 10-K · filed 2021-03-18 | $8.47M 10-K · filed 2019-03-25 |
| 2018-09-30 | $8.80M 10-Q · filed 2019-11-12 | $6.85M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $11.56M 10-Q · filed 2019-11-12 | $8.34M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $14.71M 10-Q · filed 2019-08-14 | $11.29M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $24.34M 10-K · filed 2020-03-19 | $7.73M 10-K · filed 2018-03-14 |
| 2017-09-30 | $9.76M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $9.86M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $6.65M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $9.72M 10-K · filed 2019-03-25 | |
| 2016-09-30 | $18.23M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $21.48M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $8.90M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $12.71M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $15.66M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $13.09M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$3.08M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $3.44M 10-K · filed 2017-03-27 | |
| 2014-09-30 | $4.37M 10-Q/A · filed 2015-04-15 | $11.34M 10-Q · filed 2014-11-14 |
| 2014-06-30 | -$17.92M 10-Q/A · filed 2015-04-15 | -$9.02M 10-Q · filed 2014-09-12 |
| 2014-03-31 | -$34.01M 10-Q/A · filed 2015-04-15 | -$24.11M 10-Q · filed 2014-05-20 |
| 2013-12-31 | -$22.63M 10-K · filed 2016-03-30 | -$14.22M 10-Q · filed 2014-05-20 |
| 2012-12-31 | $12.94M 10-Q/A · filed 2015-04-15 | $13.01M 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |